Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: A 12-week, randomized open-label trial

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 369-375

  Nakakura, Shunsuke ^a   Tabuchi, Hitoshi ^a   Baba, Yukio ^b   Maruiwa, Futoshi ^b   Ando, Nobuko ^b   Kanamoto, Takashi ^c   Kiuchi, Yoshiaki ^c  

^a Saneikai Tsukazaki Hospital   (Japan)

^b Baba Eye Clinic   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Brinzolamide; Dorzolamide timolol; Fixed combination; Glaucoma; Intraocular pressure; Latanoprost timolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PROSTAGLANDIN F2 ALPHA;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE BURNING; EYELID DISEASE; EYELID HYPERPIGMENTATION; FOREIGN BODY; HUMAN; INTRAOCULAR PRESSURE; KERATOPATHY; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL PUNCTATE KERATOPATHY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84859540612     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S29912     Document Type: Article

References (25)

1. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
2. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol. 1993;116:176-181.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120:701-713.
4. Chauhan BC, Mikelberg FS, Balazi AG, et al. Canadian Glaucoma Study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126:1030-1036.
5. Pappa C, Hypthantis T, Pappa S, et al. Psychiatric manifestation and personality traits associated with compliance with glaucoma treatment. J Psychosom Res. 2006;61:609-617.
6. Mackean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle Glaucoma. Br J Ophthalmol.1983;67:46-49.
7. Olthoff CMG, Schouten JSAG, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology. 2005;112:953-961.
8. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
9. Djafari F, Lesk MR, Harasymowycz PL, et al. Determination of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238-243.
10. Chawla A, McGalliard J, Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85:464.
11. Servat JJ, Bemardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011;28:267-282.
12. Sleath B, Robin A, Covert D, et al. Patient-reported behavior and problems using glaucoma medications. Ophthalmology. 2006;113: 431-436.
13. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophthalmol. 1983;67:46-49.
14. Granstrom PA. Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects. Br J Ophthalmol. 1982;66:464-474.
15. Barnebey HS, Orengo-Nania S, Flowers BE, et al. Safety and efficiency of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1-7.
16. Higginbothanm EJ, Feldman R, Stiles M, et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915-922.
17. Diestelhorst M, Larsson LI. A 12-week, randomized double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70-76.
18. Storhmaier K, Snyder E, DuBiner H, et al. The efficiency and safety of the dorzalamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105:1936-1944.
19. Hommer A; Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/ timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53-62.
20. Miyata K, Amano S, Sawa M, et al. A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch Ophthalmol. 2003;121:1537-1539.
21. Nasser QJ, Stewart WC. Glaucoma treatment and diagnostic trends. Rev Ophthalmol. 2006;13:87-93.
22. Konstas AG, Mikropoulos D, Dimopoulos AT, et al. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol. 2008;92:1498-1502.
23. Shin DH, Feldman RM, Sheu WP; Fixed Combination Latanoprost/ Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276-282.
24. Kitazawa Y, Azuma I, Iwata K, et al. Dorzaloamide, a topical carbonic anhydrade inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma. 1994;3:275-279.
25. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1992;110:495-499.